|Mr. Christophe Weber||Pres, CEO & Representative Director||8.71M||N/A||1966|
|Mr. Constantine Saroukos||CFO & Director||4.59M||N/A||1971|
|Dr. Andrew S. Plump||Pres of R&D and Director||5.16M||N/A||1965|
|Dr. Seigo Izumo||Chair of Management Board||N/A||N/A||N/A|
|Mr. Haruhiko Hirate||Member of Management Board||N/A||N/A||1957|
|Salvatore Alesci||Member of Management Board and Head of R&D Global Science & Biomedical Policy||N/A||N/A||N/A|
|Mr. Iwaaki Taniguchi||Sr. VP of Corp. Fin. & Controlling Department||N/A||N/A||N/A|
|Mr. Christopher David O'Reilly||Global Head of Investor Relations & Global Fin.||N/A||N/A||N/A|
|Mr. Yoshihiro Nakagawa||Global Gen. Counsel||N/A||N/A||1960|
|Ms. Mwana Lugogo||Chief Ethics & Compliance Officer||N/A||N/A||1970|
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 1 April 2021 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 5; Compensation: 1.